CJ Bioscience to Participate in the World's Largest Microbiome Conference 'IHMC 2026'

To Be Held at COEX from June 3 to 5

CJ Bioscience announced on June 1 that it will participate in the 11th International Human Microbiome Consortium (IHMC 2026), which will be held at COEX in Seoul from June 3 to 5, where the company plans to share its core research achievements in personalized wellness and its differentiated strategies for next-generation new drug pipelines.

Since its launch in 2008, IHMC has been the world’s premier international academic conference where leading scholars, industry experts, and clinical professionals gather to share the latest R&D trends in human microbiome research. This year marks the first time the event will be held in Korea, with over 1,000 bio experts from around the globe attending, including world-renowned scholars such as Professor Ramnik J. Xavier of Harvard Medical School and Professor Ruth E. Ley of the Max Planck Institute.

During the conference, CJ Bioscience plans to showcase its globally recognized microbiome technological capabilities through various activities, including main session presentations, hosting a luncheon session, and poster presentations.

In particular, during the "Luncheon Session" on June 3, Professor Oh Beomjo of the Department of Family Medicine at Seoul National University Boramae Medical Center will publicly announce, for the first time, the results of human intervention studies using personalized microbiome materials. This research utilized the company’s core technologies, including its human gut simulation system and AI algorithms. Based on these findings, the company intends to launch personalized products in earnest in the second half of this year and expand into clinical research aimed at improving side effects of obesity treatments.

Notably, this conference will also feature the presentation of research results on the "Personalized Diet Analysis Index (Diet Index)," which can predict gut microbial health based on individual dietary habits. The company plans to further advance this technology and develop a diverse range of personalized wellness businesses in the future.

In addition, on the final day of the conference, June 5, the "Microbiome Industry Spotlight Session" will present the development strategy for CJRB-201, a Faecalibacterium-based new drug candidate pipeline targeting inflammatory bowel disease (IBD), as well as announce differentiated non-clinical research achievements.

A CJ Bioscience representative stated, "IHMC 2026 will serve as a milestone event to promote the status of Korea’s microbiome industry in the global market and as an opportunity for CJ Bioscience to showcase its world-class MB Science (microbiome technology) capabilities. Based on our differentiated R&D data, we will gain recognition for the value of our new drug pipelines in the global market and officially diversify and expand our business into the health and wellness sector."

This content was produced with the assistance of AI translation services.